<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622907</url>
  </required_header>
  <id_info>
    <org_study_id>HISTORIC AF 2011-10-11</org_study_id>
    <nct_id>NCT01622907</nct_id>
  </id_info>
  <brief_title>Hybrid Staged Operating Room and Interventional Catheter Ablation for Atrial Fibrillation</brief_title>
  <acronym>HISTORIC-AF</acronym>
  <official_title>European Multicenter Study Using Hybrid Staged Operating Room and Interventional Catheter Ablation Techniques to Treat Chronic AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial SrL</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, investigator-driven trial. This study hypothesizes that combining
      surgical endoscopic and transcatheter techniques in a staged fashion provides superior
      clinical outcomes than isolated surgical/EP approaches in patients with persistent AF lasting
      &gt; 1 year but &gt; 5 years.

      The proposed procedure involves the creation of cardiac lesions with epicardially applied
      radiofrequency (RF) ablation through a minimally invasive surgical (MIS) approach followed by
      a delayed EP ablation procedure performed at 1-2 months from the surgical operation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New ablative technologies have been developed to simplify the original &quot;cut and sew&quot; Cox Maze
      procedure so that it can now be used for routine treatment of AF in patients undergoing
      open-heart surgery, as well as in a stand-alone arrhythmia procedure. A minimally invasive,
      thoracoscopic surgical treatment of AF is able to address both the triggers for AF by
      pulmonary vein isolation and the left posterior atrial wall exclusion, which after the
      pulmonary veins is the next most important atrial substrate in the promotion of AF.

      New hybrid procedures attempt to combine the success rate and the minimally invasive nature
      of thoracoscopic mini-Maze with the effectiveness and short recovery times associated with
      catheter ablation. The key is blocking signals that cause the arrhythmia from both outside
      (epicardial) and inside (endocardial) the heart.

      Suboptimal results of both catheter ablation and surgery suggest that success in the
      treatment of long standing persistent AF and persistent lone AF will benefit from a close
      collaboration between the cardiothoracic surgeon and the electrophysiologist, to offer
      patients the best available combination of treatments for any given set of cardiovascular
      lesions.

      Hybrid treatment for AF is being increasingly adopted in Europe and the United States and has
      been assessed for the treatment of AF at the Coordinating Center (Brescia, Italy) with
      promising results.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PRIMARY EFFICACY ENDPOINT: 24-hour Holter monitoring</measure>
    <time_frame>9 months following the end of the blanking period</time_frame>
    <description>The primary efficacy endpoint is the rate of therapeutic success, with a target rate of &gt; 60%. Therapeutic success is defined as freedom from AF, during the 9 months following the end of the blanking period, based on 24-hour Holter monitor results, and freedom from AADs beginning at 6 months following surgery. The blanking period is 3 months following the surgical ablation procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SECONDARY EFFICACY ENDPOINTS: 24-hour Holter monitoring</measure>
    <time_frame>9 months following the end of the blanking period</time_frame>
    <description>Rate of therapeutic success is defined as freedom from AF, 9 months following the end of the blanking period, based on 24-hour Holter monitoring. The target success rate is &gt;60%. Rate of therapeutic success is defined as freedom from AF, during the 9 months following the end of the blanking period.The blanking period is 3 months following the surgical ablation procedure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pts Symptomatic Recurrent Persistent AF</arm_group_label>
    <description>Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for &gt; 1-year &lt; 5 years duration</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Symptomatic Recurrent Persistent AF or Long Standing Persistent AF, defined
        as persistent AF for greater than 1-year but less than 5 years duration (according to the
        HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial
        Fibrillation)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be treated initially by thorocoscopic epicardial surgical RF ablation to
             create a box lesion around the pulmonary veins, ganglionated plexi, and superior vena
             cava-inferior vena cava (SVC-IVC) connecting lesions.

        Four to maximum 8 weeks following the surgical ablation procedure, the patient is returning
        to the EP Laboratory to:

        Assess integrity of the Box lesion Eliminate gaps in the surgical lesions when found
        Terminate fragmented potentials Perform a Caval-Tricuspid Isthmus (CTI) lesion line Upon
        completion of this procedure, integrity of the lesions is reassessed just prior to
        withdrawing the EP catheters from the LA.

        Exclusion Criteria:

          -  History of Recurrent Persistent or Long Standing Persistent AF for more than 5 years;
             Documented left atrial size (AP diameter) greater than 55 mm; Documented left
             ventricular ejection fraction (LVEF) of 40% or less; History of cerebrovascular
             disease, including stroke or transient ischemic attack (TIA) within 6 months prior to
             enrollment; Significant underlying structural heart disease requiring surgical or
             procedural intervention; Previous heart surgery; Chronic obstructive pulmonary disease
             (&lt; 70% predictive lung function); Contraindication to anticoagulant therapy, or
             inability to comply with anticoagulant therapy; Other clinical conditions precluding
             inclusion (e.g., organ disease, disturbances of hemostasis, etc.); Pregnancy, planned
             pregnancy or breastfeeding; Concomitant cardiac surgery procedure planned.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CLAUDIO MUNERETTO, PROF.</last_name>
    <role>Study Chair</role>
    <affiliation>UNIV. HOSP. SPEDALI CIVILI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio Muneretto, Prof.</last_name>
    <phone>+39 0303 995004</phone>
    <email>munerett@med.unibs.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Curnis, MD.</last_name>
    <email>antonio.curnis@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Louis Pradel Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FRANCOIS OBADIA, PROF.</last_name>
      <email>jean-francois.obadia@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>FRANCOIS OBADIA, PROF.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center Brandenburg- Immanuel</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JOHANNES ALBES, PROF.</last_name>
    </contact>
    <investigator>
      <last_name>JOHANNES ALBES, PROF.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtische Kliniken</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RALF KRAKOR, MD.</last_name>
      <email>ralf.krakor@debitel.de</email>
    </contact>
    <investigator>
      <last_name>RALF KRAKOR, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamburg Uke</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CHRISTIAN DETTER, MD</last_name>
      <email>detter@uke.de</email>
    </contact>
    <investigator>
      <last_name>CHRISTIAN DETTER, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GIAMPIERO ESPOSITO, MD</last_name>
      <email>espositogp@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>GIAMPIERO ESPOSITO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. Hosp. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CLAUDIO - MUNERETTO, Prof.</last_name>
      <phone>+39 030 3996401</phone>
      <email>munerett@med.unibs.it</email>
    </contact>
    <investigator>
      <last_name>Claudio - Muneretto, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio - Curnis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ.Hosp. Molinette</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MAURO RINALDI, MD</last_name>
      <email>mauro.rinaldi@unito.it</email>
    </contact>
    <investigator>
      <last_name>MAURO RINALDI, PROF.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Krakau</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>. JERZY SADOWSKI SADOWSKI, PROF.</last_name>
      <email>jsadowski@szpitaljp2.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>JERZY SADOWSKI, PROF.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ROBERTO CASULA</last_name>
      <email>rpcasula@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>ROBERTO CASULA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ANTHONY DE SOUZA, Mr.</last_name>
      <email>T.DeSouza@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>ANTHONY DE SOUZA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.civile.spedalicivili.brescia.it/servizi/unitaoperative/unitaoperative_fase02.aspx?ID=960</url>
    <description>Study Coordinating Center Website</description>
  </link>
  <link>
    <url>http://www.meditrial.it</url>
    <description>Clinical Research Organization</description>
  </link>
  <reference>
    <citation>Bisleri G, Curnis A, Bottio T, Mascioli G, Muneretto C. The need of a hybrid approach for the treatment of atrial fibrillation. Heart Surg Forum. 2005;8(5):E326-30. Review.</citation>
    <PMID>16099734</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Claudio Muneretto</investigator_full_name>
    <investigator_title>M.D., Professor. Director, Department of Cardiac Surgery</investigator_title>
  </responsible_party>
  <keyword>Catheter ablation, radiofrequency</keyword>
  <keyword>Epicardially applied radiofrequency ablation</keyword>
  <keyword>Minimally invasive surgical approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 29, 2016</submitted>
    <returned>November 17, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

